Angiogenesis in the eye stands as a big reason for blindness and vision impairment in both developed and developing countries including age-related macular degeneration especially Exudative age-related macular degeneration, Proliferative Diabetic Retinopathy, Diabetic Macular Oedema, Glaucoma and Cataract. Amongst these, Age-related macular degeneration ranks third globally as a cause of visual impairment and central vision loss in industrialized and middle-income countries, raising a major concern for more effective and affordable treatment. Age-related macular Degeneration is a retinal disorder which occur due to low blood circulation in retinal and macular region causing degeneration in macular retina and central vision loss. For the treatment of disease, dosage forms used are administered through intravitreal route in the form of Pre-filled syringes and they are regulated as Combination product by USFDA (United States Food and Drug Administration) (21 CFR 3.2(e))in USA and by directive 93/42/EEC in European Union. This Age-related Macular Degeneration is associated with serious consequences in person’s life starting from loss of independence, depression to even increased financial outcome, requiring more focus over effective therapies. For this, concerns for availability of New medications and also easy identification of patients with risk factors of Age-related Macular Degeneration is becoming more significant. This review article gives detailed information about Age-related macular degeneration, procedure for its diagnosis and various treatment options available along with regulatory requirements to be fulfilled for the dosage forms meant for treatment. This article also explains the challenges associated with macular degeneration market and future products in pipeline.
Impact Factor
2022: 6.012
This work is licensed under a